The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Antibody-drug conjugates—an emerging class of cancer treatment
Open accessAbstract
Antibody-drug conjugates (ADCs) are an emerging novel class of anticancer treatment agents that combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. New linker technology associated with novel highly potent cytotoxic payloads has permitted the development of more effective and safe ADCs. In recent years, two ADCs have been licensed, T-DM1 and brentuximab vedotin, and are already establishing their place in cancer treatment. A plethora of ADCs are being investigated in phases I and II trials, emerging data of which appears promising. As we deepen our understanding of what makes a successful ADC, an increasing number of ADCs will likely become viable treatment options as single agents or in combination with chemotherapy. This review will present the philosophy underlying ADCs, their main characteristics and current research developments with a focus on ADCs in solid tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“Clonal expansion of resistant cells and intratumoural heterogeneity representing populations of cells that are resistant de novo within the same tumour, are likely to influence resistance to ADCs (Gerlinger et al, 2012).”
BackgroundTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 997
Cancer stem cells: mirage or reality?
Gupta, P. B., Chaffer, C. L., & Weinberg, R. A. (2009) · Nature Medicine · doi:10.1038/nm0909-1010 · Cited by 979
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763
Site-specific antibody drug conjugates for cancer therapy
Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R. (2014) · mAbs · doi:10.4161/mabs.27022 · Cited by 676
Petersdorf, S. H., Kopecky, K. J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, R. A., Erba, H. P., Stiff, P. J., Stuart, R. K., et al. (2013) · Blood · doi:10.1182/blood-2013-01-466706 · Cited by 638
Agarwal, P., & Bertozzi, C. R. (2015) · Bioconjugate Chemistry · doi:10.1021/bc5004982 · Cited by 605
Trastuzumab emtansine: mechanisms of action and drug resistance
Barok, M., Joensuu, H., & Isola, J. (2014) · Breast Cancer Research · doi:10.1186/bcr3621 · Cited by 595
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Junttila, T. T., Li, G., Parsons, K., Phillips, G. L., & Sliwkowski, M. X. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1090-x · Cited by 541
Antibody–drug conjugates: current status and future directions
Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.004 · Cited by 470
LoRusso, P. M., Weiss, D., Guardino, E., Girish, S., & Sliwkowski, M. X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0762 · Cited by 444
Antibody Conjugate Therapeutics: Challenges and Potential
Teicher, B. A., & Chari, R. V. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1417 · Cited by 427
Maturing antibody–drug conjugate pipeline hits 30
Mullard, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4009 · Cited by 295
Antibody‐Drug Conjugates for the Treatment of Cancer
Flygare, J. A., Pillow, T. H., & Aristoff, P. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12085 · Cited by 232
Baselga, J., Lewis Phillips, G. D., Verma, S., Ro, J., Huober, J., Guardino, A. E., Samant, M. K., Olsen, S., de Haas, S. L., & Pegram, M. D. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2499 · Cited by 230
Update on Metastatic Gastric and Esophageal Cancers
Shah, M. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.1799 · Cited by 213
Antibody–drug conjugates: Basic concepts, examples and future perspectives
Casi, G., & Neri, D. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.026 · Cited by 210
Moldenhauer, G., Salnikov, A. V., Lüttgau, S., Herr, I., Anderl, J., & Faulstich, H. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs140 · Cited by 199
Phillips, G. D. L., Fields, C. T., Li, G., Dowbenko, D., Schaefer, G., Miller, K., Andre, F., Burris, H. A., Albain, K. S., Harbeck, N., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0358 · Cited by 198
Antibody–drug conjugates—A new wave of cancer drugs
Bouchard, H., Viskov, C., & Garcia-Echeverria, C. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.10.021 · Cited by 190
Antibody–drug conjugates for cancer: poised to deliver?
Hughes, B. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3270 · Cited by 188
SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
Blanc, V., Bousseau, A., Caron, A., Carrez, C., Lutz, R. J., & Lambert, J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0485 · Cited by 170
Antibody-targeted drugs and drug resistance—Challenges and solutions
Shefet-Carasso, L., & Benhar, I. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.001 · Cited by 159
Curative Properties of Noninternalizing Antibody–Drug Conjugates Based on Maytansinoids
Perrino, E., Steiner, M., Krall, N., Bernardes, G. J. L., Pretto, F., Casi, G., & Neri, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2990 · Cited by 130
Monoclonal antibody-based therapies in cancer: Advances and challenges
Sapra, P., & Shor, B. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.03.004 · Cited by 125
Investigational antibody drug conjugates for solid tumors
Sapra, P., Hooper, A. T., O’Donnell, C. J., & Gerber, H. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.582866 · Cited by 92
Gerber, H., Sutherland, M. K., Stone, I. J., Morris-Tilden, C. A., Miyamoto, J. B., McCormick, R. S., Alley, S. C., Okeley, N. M., Hayes, B., Hernandez‐Ilizaliturri, F. J., et al. (2009) · Blood · doi:10.1182/blood-2008-09-179143 · Cited by 85
Sapra, P., Damelin, M. I., DiJoseph, J. F., Marquette, K., Geles, K. G., Golas, J., Dougher, M. M., Narayanan, B., Giannakou, A., Khandke, K. M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0603 · Cited by 81
Cohen, R., Vugts, D. J., Visser, G. W. M., van Walsum, M., Bolijn, M., Spiga, M., Lazzari, P., Shankar, S. P., Sani, M., Zanda, M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1141 · Cited by 73
Challenges in SN38 drug delivery: current success and future directions
Palakurthi, S. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1070142 · Cited by 72
Radioimmunoconjugates for the Treatment of Cancer
Kraeber‐Bodéré, F., Bodet‐Milin, C., Rousseau, C., Eugène, T., Pallardy, A., Frampas, É., Carlier, T., Ferrer, L., Gaschet, J., Davodeau, F., et al. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.07.004 · Cited by 72
Palumbo, A., Hauler, F., Dziunycz, P., Schwager, K., Soltermann, A., Pretto, F., Alonso, C., Hofbauer, G. F. L., Boyle, R. W., & Neri, D. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.78 · Cited by 72
Boghaert, E. R., Khandke, K. M., Sridharan, L., Dougher, M. M., DiJoseph, J. F., Kunz, A., Hamann, P. R., Moran, J. K., Chaudhary, I., & Damle, N. K. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0560-2 · Cited by 63
ten Cate, B., Bremer, E., de Bruyn, M., Bijma, T., Samplonius, D. F., Schwemmlein, M., Huls, G. A., Fey, G. H., & Helfrich, W. (2009) · Leukemia · doi:10.1038/leu.2009.34 · Cited by 63
The Next Generation of Antibody Drug Conjugates
Mack, F. A., Ritchie, M. F., & Sapra, P. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.001 · Cited by 50
Cited by
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Tsuchikama, K., & An, Z. (2018) · Protein & Cell · doi:10.1007/s13238-016-0323-0 · Cited by 786
Transport of drugs from blood vessels to tumour tissue
Dewhirst, M. W., & Secomb, T. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.93 · Cited by 749
Metadata
- Authors
- Diamantis, N., & Banerji, U.
- Venue
- British Journal of Cancer
- Published
- 2016-01-07
- Volume
- 114
- Issue
- 4
- Pages
- 362-367
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2226317100
- Cited by
- 525
- References
- 42
- FWCI
- 57.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.